Anuh Pharma
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Anuh Pharma's board approved an investment in manufacturing assets to expand production capacity and a proposal to borrow up to ₹75 crore for the purchase. The investment amount, asset details and capacity addition were not specified, with further details to follow once transaction terms were finalised. The company's installed base stood at 2,400 MTPA following expansions from 1,500 MTPA across FY23 to FY25. It reported total revenue of about ₹776 crore in FY26 and held cash and investments of about ₹115 crore with no long-term debt. The Tarapur site served as its API manufacturing site.
Powered by Tijori
Anuh Pharma's board approved an investment in manufacturing assets to expand production capacity and a proposal to borrow up to ₹75 crore for the purchase. The investment amount, asset details and capacity addition were not specified, with further details to follow once transaction terms were finalised. The company's installed base stood at 2,400 MTPA following expansions from 1,500 MTPA across FY23 to FY25. It reported total revenue of about ₹776 crore in FY26 and held cash and investments of about ₹115 crore with no long-term debt. The Tarapur site served as its API manufacturing site.
Powered by Tijori
March 6 (Reuters) - Anuh Pharma Ltd ANUH.NS:
ANUH PHARMA LTD - MAHARASHTRA FACILITY UNDERGONE AUDIT BY EDQM
ANUH PHARMA LTD - FACILITIES WERE FOUND TO BE COMPLIANT DURING EDQM AUDIT
Further company coverage: ANUH.NS
(([email protected];))
March 6 (Reuters) - Anuh Pharma Ltd ANUH.NS:
ANUH PHARMA LTD - MAHARASHTRA FACILITY UNDERGONE AUDIT BY EDQM
ANUH PHARMA LTD - FACILITIES WERE FOUND TO BE COMPLIANT DURING EDQM AUDIT
Further company coverage: ANUH.NS
(([email protected];))
Aug 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA JUNE-QUARTER PAT 95.1 MILLION RUPEES
ANUH PHARMA JUNE-QUARTER REVENUE FROM OPERATIONS 1.38 BILLION RUPEES
Source text for Eikon: ID:nBSE82kZjz
Further company coverage: ANUH.BO
(([email protected];))
Aug 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA JUNE-QUARTER PAT 95.1 MILLION RUPEES
ANUH PHARMA JUNE-QUARTER REVENUE FROM OPERATIONS 1.38 BILLION RUPEES
Source text for Eikon: ID:nBSE82kZjz
Further company coverage: ANUH.BO
(([email protected];))
April 4 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA LTD - APPROVED INVESTMENT IN HUOBAN ENERGY 5 FOR SOLAR PROJECT
Source text for Eikon: ID:nBSE7xCRTk
Further company coverage: ANUH.BO
(([email protected];))
April 4 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA LTD - APPROVED INVESTMENT IN HUOBAN ENERGY 5 FOR SOLAR PROJECT
Source text for Eikon: ID:nBSE7xCRTk
Further company coverage: ANUH.BO
(([email protected];))
Feb 28 (Reuters) - Anuh Pharma Ltd ANUH.BO:
APPROVAL FROM EDQM FOR CEP OF SULFADOXINE API WHICH IS AN ANTI-MALARIAL DRUG
Source text for Eikon: ID:nBSE75hVMs
Further company coverage: ANUH.BO
(([email protected];))
Feb 28 (Reuters) - Anuh Pharma Ltd ANUH.BO:
APPROVAL FROM EDQM FOR CEP OF SULFADOXINE API WHICH IS AN ANTI-MALARIAL DRUG
Source text for Eikon: ID:nBSE75hVMs
Further company coverage: ANUH.BO
(([email protected];))
Feb 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA LTD DEC-QUARTER PAT 191.1 MILLION RUPEES VERSUS 93.1 MILLION RUPEES
ANUH PHARMA LTD DEC-QUARTER REVENUE FROM OPERATIONS 1.72 BILLION RUPEES VERSUS 1.39 BILLION RUPEES
Source text for Eikon: ID:nBSE83lMqK
Further company coverage: ANUH.BO
(([email protected];))
Feb 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA LTD DEC-QUARTER PAT 191.1 MILLION RUPEES VERSUS 93.1 MILLION RUPEES
ANUH PHARMA LTD DEC-QUARTER REVENUE FROM OPERATIONS 1.72 BILLION RUPEES VERSUS 1.39 BILLION RUPEES
Source text for Eikon: ID:nBSE83lMqK
Further company coverage: ANUH.BO
(([email protected];))
Aug 11 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ECEIVED APPROVAL FROM EDQM FOR CEP OF GLICLAZIDE API
Source text for Eikon: ID:nBSE1RMk0L
Further company coverage: ANUH.BO
(([email protected];))
Aug 11 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ECEIVED APPROVAL FROM EDQM FOR CEP OF GLICLAZIDE API
Source text for Eikon: ID:nBSE1RMk0L
Further company coverage: ANUH.BO
(([email protected];))
July 13 (Reuters) - Anuh Pharma Ltd ANUH.BO:
RECEIVED APPROVAL FROM EDQM FOR CEP OF AZITHROMYCIN API, A BROAD SPECTRUM MACROLIDE ANTIBIOTIC
Further company coverage: ANUH.BO
(([email protected];))
July 13 (Reuters) - Anuh Pharma Ltd ANUH.BO:
RECEIVED APPROVAL FROM EDQM FOR CEP OF AZITHROMYCIN API, A BROAD SPECTRUM MACROLIDE ANTIBIOTIC
Further company coverage: ANUH.BO
(([email protected];))
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Anuh Pharma do?
Anuh Pharma Ltd is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and also deals in bulk drugs, chemicals, and pharmaceutical formulations.
Who are the competitors of Anuh Pharma?
Anuh Pharma major competitors are Kilitch Drugs(India), Zim Laboratories, Wanbury, Shivalik Rasayan, Lincoln Pharma, Bharat Parenterals, Albert David. Market Cap of Anuh Pharma is ₹871 Crs. While the median market cap of its peers are ₹732 Crs.
Is Anuh Pharma financially stable compared to its competitors?
Anuh Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Anuh Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Anuh Pharma latest dividend payout ratio is 36.63% and 3yr average dividend payout ratio is 24.45%
How has Anuh Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable
How strong is Anuh Pharma balance sheet?
Balance sheet of Anuh Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Anuh Pharma improving?
The profit is oscillating. The profit of Anuh Pharma is ₹44.17 Crs for TTM, ₹41.05 Crs for Mar 2026 and ₹47.35 Crs for Mar 2025.
Is the debt of Anuh Pharma increasing or decreasing?
Yes, The net debt of Anuh Pharma is increasing. Latest net debt of Anuh Pharma is -₹16.59 Crs as of Mar-26. This is greater than Mar-25 when it was -₹28.96 Crs.
Is Anuh Pharma stock expensive?
Yes, Anuh Pharma is expensive. Latest PE of Anuh Pharma is 19.71, while 3 year average PE is 17.51. Also latest EV/EBITDA of Anuh Pharma is 13.3 while 3yr average is 12.73.
Has the share price of Anuh Pharma grown faster than its competition?
Anuh Pharma has given lower returns compared to its competitors. Anuh Pharma has grown at ~10.75% over the last 8yrs while peers have grown at a median rate of 12.94%
Is the promoter bullish about Anuh Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Anuh Pharma is 71.8% and last quarter promoter holding is 71.8%.
Are mutual funds buying/selling Anuh Pharma?
There is Insufficient data to gauge this.